HCV Treatment
HCV Polymerase Inhibitor PSI-938 Gets Fast Track Status
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 August 2011 00:00
- Written by Pharmasset
The U.S. Food and Drug Administration (FDA) last week granted a "fast track" designation for PSI-938, an investigational nucleotide analog hepatitis C virus (HCV) polymerase inhibitor being developed by Pharmasset.
Insulin Resistance Affects Sustained Response to Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Wednesday, 24 August 2011 00:00
- Written by Liz Highleyman
Greater insulin resistance was association with poorer response to pegylated interferon plus ribavirin regardless of hepatitis C virus (HCV) genotype, according to a meta-analysis described in the August 2011 issue of Alimentary Pharmacology and Therapeutics.
TAG Offers New Guide to Clinical Trials for People with Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 17 August 2011 00:00
- Written by Liz Highleyman
The Treatment Action Group (TAG) has produced a new booklet for people considering taking part in clinical trials for new therapies for hepatitis C.
Telaprevir (Incivek) Approved in Canada
- Details
- Category: HCV Treatment
- Published on Wednesday, 24 August 2011 00:00
- Written by Press Release
The hepatitis C virus (HCV) protease inhibitor telaprevir (brand name Incivek) -- one of the first 2 direct-acting antiviral drugs for genotype 1 chronic hepatitis C -- was approved in Canada this week. Telaprevir and another HCV protease inhibitor, boceprevir (Victrelis), were approved by the U.S. Food and Drug Administration (FDA) this past May.
FDA Updates Dosing of Pegasys plus Ribavirin for Hepatitis C Patients with Kidney Impairment
- Details
- Category: Drug Advisories & Warnings
- Published on Friday, 12 August 2011 00:00
- Written by FDA
On August 9, 2011, the U.S. Food and Drug Administration (FDA) approved changes to the product label information for pegylated interferon alfa-2a (Pegasys) plus the Copegus brand of ribavirin, reflecting new dose recommendations for people with impaired kidney function.
Web Design and Development by